University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Maxwell Meng, M.D.

Urologic cancer surgeon

Dr. Maxwell Meng is a surgeon specializing in urologic cancers and laparoscopy. His clinical interests include the diagnosis and management of genitourinary malignancy and minimally invasive treatment of benign and malignant diseases. Meng, actively involved in developing new treatment technologies, is also experienced in robotic surgery.

Meng earned a medical degree at Johns Hopkins School of Medicine and completed general surgery and urology training at UCSF, where he also completed fellowships in urologic oncology and minimally invasive surgery. He is an associate professor in the UCSF Department of Urology.


Prostate Cancer Center
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Urologic Surgery and Oncology
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Maxwell Meng


John Hopkins University 1995


UCSF Urology Dept., Urology 2001


UCSF Urology Dept., Urology 2002

Selected Research and Publications

  1. Meng MV. Editorial comment for zargar et Al. J Endourol. 2015 Jan; 29(1):102.
  2. Meng MV, Boughey JC. Treating metastatic prostate cancer now and in the future. Bull Am Coll Surg. 2014 Sep; 99(9):55-7.
  3. Hampson LA, Brajtbord JS, Meng MV. The future of quality in urologic oncology: evaluating the horizon of surgical standards. Urol Oncol. 2014 Aug; 32(6):735-40.
  4. Meng M. Commentary on "Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study." Schutz FA, Pomerantz MM, Gray KP, Atkins MB, Rosenberg JE, Hirsch MS, McDermott DF, Lampron ME, Lee GS, Signoretti S, Kantoff PW, Freedman ML, Choueiri TK, Dana-Farber Cancer Institute, Boston, MA 02115.: Lancet Oncol 2013;14(1):81-87. [Epub 2012 Dec 7]. doi: 10.1016/S1470-2045(12)70517-X. Erratum in, Lancet Oncol 2013;14(3):e89. Urol Oncol. 2014 May; 32(4):512-3.
  5. Hsieh MH, Meng MV. Prostate Cancer Screening and Risk of Litigation: Caught between Scylla and Charybdis. J Urol. 2014 Jun; 191(6):1648-9.
  6. Morgan TM, Meng MV, Cooperberg MR, Cowan JE, Weinberg V, Carroll PR, Lin DW. A risk-adjusted definition of biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2014 Jun; 17(2):174-9.
  7. Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M, Carroll PR. Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes. PLoS One. 2014; 9(3):e89754.
  8. Meng M, Gao X, Han LJ, Li XY, Wu D, Li HZ, Chen QJ. Correlation analysis between starch properties and single nucleotide polymorphisms of waxy genes in common rye (Secale cereale L.). Genet Mol Res. 2014; 13(2):2574-89.
  9. Whitson JM, Meng M. Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data. BJU Int. 2014 Jan; 113(1):2-3.
  10. Friedman GD, Schwalbe J, Achacoso N, Meng MV, Kroenke CH, Habel LA. Antidepressants and testicular cancer. Cancer Causes Control. 2014 Feb; 25(2):251-8.
  11. Benner C, Greenberg M, Shepard N, Meng MV, Rabow MW. The natural history of symptoms and distress in patients and families following cystectomy for treatment of muscle invasive bladder cancer. J Urol. 2014 Apr; 191(4):937-42.
  12. Cary KC, Cowan JE, Sanford M, Shinohara K, Perez N, Chan JM, Meng MV, Carroll PR. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies. Eur Urol. 2014 Aug; 66(2):337-42.
  13. Meng MV. Editorial comment. Urology. 2013 Sep; 82(3):545-6.
  14. Meng MV, Nelson H. What is the appropriate extent of lymphadenectomy for bladder cancer? Bull Am Coll Surg. 2013 Jul; 98(7):60-2.
  15. Odisho AY, Washington SL, Meng MV, Cowan JE, Simko JP, Carroll PR. Benign prostate glandular tissue at radical prostatectomy surgical margins. Urology. 2013 Jul; 82(1):154-9.
  16. Punnen S, Meng MV, Cooperberg MR, Greene KL, Cowan JE, Carroll PR. How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer? BJU Int. 2013 Aug; 112(4):E314-20.
  17. Fung-Kee-Fung SD, Porten SP, Meng MV, Kuettel M. The role of active surveillance in the management of prostate cancer. J Natl Compr Canc Netw. 2013 Feb 1; 11(2):183-7.
  18. Meng MV. Commentary on "Laparoendoscopic single-site (LESS) partial nephrectomy short-term outcomes." Rais-Bahrami S, George AK, Montag S, Okhunov Z, Richstone L, The Arthur Smith Institute for Urology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY: BJU Int 2012 (Epub ahead of print). Urol Oncol. 2013 Jan; 31(1):131-2.
  19. Meng MV. Commentary on "Radiofrequency ablation of incidental benign small renal mass: outcomes and follow-up protocol." Tan YK, Best SL, Olweny E, Park S, Trimmer C, Cadeddu JA, Department of Urology, University of Texas Southwestern Medical School, Dallas, Texas, TX. Urol Oncol. 2013 Jan; 31(1):132-3.
  20. Meng MV. Commentary on "Predicting the histology of small renal masses using preoperative dynamic contrast-enhanced magnetic resonance imaging." Kim JH, Bae JH, Lee KW, Kim ME, Park SJ, Park JY, Department of Urology, Soonchunhyang University Hospital, Seoul, Korea. Urol Oncol. 2013 Jan; 31(1):133-4.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.